Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults

•In 1,485 older nonmuscle-invasive bladder cancer patients from 2 health systems, 23% had metabolic syndrome.•Metabolic syndrome patients were mostly males and current or former smokers.•Over median follow up of 6 years, one-third of patients had a recurrence.•We found no association between metabol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2020-09, Vol.38 (9), p.737.e17-737.e23
Hauptverfasser: Garg, Tullika, Young, Amanda J., O'Keeffe-Rosetti, Maureen, McMullen, Carmit K., Nielsen, Matthew E., Murphy, Terrence E., Kirchner, H. Lester
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 737.e23
container_issue 9
container_start_page 737.e17
container_title Urologic oncology
container_volume 38
creator Garg, Tullika
Young, Amanda J.
O'Keeffe-Rosetti, Maureen
McMullen, Carmit K.
Nielsen, Matthew E.
Murphy, Terrence E.
Kirchner, H. Lester
description •In 1,485 older nonmuscle-invasive bladder cancer patients from 2 health systems, 23% had metabolic syndrome.•Metabolic syndrome patients were mostly males and current or former smokers.•Over median follow up of 6 years, one-third of patients had a recurrence.•We found no association between metabolic syndrome and time to nonmuscle-invasive bladder cancer recurrence. Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. We identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems’ electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index >30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70–1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.
doi_str_mv 10.1016/j.urolonc.2020.04.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2404045984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1078143920301502</els_id><sourcerecordid>2404045984</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-a06b7164c0cd7b51091e20fb59ce4cf03a8aa444fa6684b6c000552c03dc9bc3</originalsourceid><addsrcrecordid>eNqFkE1rHDEMQE1JadK0P6HFx1xmIs94vk4lhLQNLPSSu7FlDXjx2Kk9syX_vl52k2vQQTI8SdZj7JuAWoDob_f1lqKPAesGGqhB1iDgA7sS49BWjZz6i1LDMFZCttMl-5zzHkDIUYhP7LJtJExiGq7Y_i7niE6vLgZuaP1HFPhCqzbRO-T5JdgUF-I6WJ4It5QoIPE48xDDsmX0VLlw0NkdiBuvraXEURcmcRd49Me3tptf8xf2cdY-09dzvmZPPx-e7n9Xuz-_Hu_vdhVK0ayVht4MopcIaAfTifJRamA23YQkcYZWj1pLKWfd96M0PQJA1zUIrcXJYHvNbk5jn1P8u1Fe1eIykvc6UNyyKqeX6KZRFrQ7oZhizolm9ZzcotOLEqCOltVenS2ro2UFUhXLpe_7ecVmFrJvXa9aC_DjBFC58-AoqYzuKM66InFVNrp3VvwHkcuS7Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404045984</pqid></control><display><type>article</type><title>Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults</title><source>Access via ScienceDirect (Elsevier)</source><creator>Garg, Tullika ; Young, Amanda J. ; O'Keeffe-Rosetti, Maureen ; McMullen, Carmit K. ; Nielsen, Matthew E. ; Murphy, Terrence E. ; Kirchner, H. Lester</creator><creatorcontrib>Garg, Tullika ; Young, Amanda J. ; O'Keeffe-Rosetti, Maureen ; McMullen, Carmit K. ; Nielsen, Matthew E. ; Murphy, Terrence E. ; Kirchner, H. Lester</creatorcontrib><description>•In 1,485 older nonmuscle-invasive bladder cancer patients from 2 health systems, 23% had metabolic syndrome.•Metabolic syndrome patients were mostly males and current or former smokers.•Over median follow up of 6 years, one-third of patients had a recurrence.•We found no association between metabolic syndrome and time to nonmuscle-invasive bladder cancer recurrence. Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. We identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems’ electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index &gt;30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70–1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.</description><identifier>ISSN: 1078-1439</identifier><identifier>EISSN: 1873-2496</identifier><identifier>DOI: 10.1016/j.urolonc.2020.04.010</identifier><identifier>PMID: 32409197</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Bladder cancer;Geriatric oncology;Outcomes;Metabolic syndrome;Multiplechronic conditions</subject><ispartof>Urologic oncology, 2020-09, Vol.38 (9), p.737.e17-737.e23</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-a06b7164c0cd7b51091e20fb59ce4cf03a8aa444fa6684b6c000552c03dc9bc3</citedby><cites>FETCH-LOGICAL-c412t-a06b7164c0cd7b51091e20fb59ce4cf03a8aa444fa6684b6c000552c03dc9bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.urolonc.2020.04.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32409197$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garg, Tullika</creatorcontrib><creatorcontrib>Young, Amanda J.</creatorcontrib><creatorcontrib>O'Keeffe-Rosetti, Maureen</creatorcontrib><creatorcontrib>McMullen, Carmit K.</creatorcontrib><creatorcontrib>Nielsen, Matthew E.</creatorcontrib><creatorcontrib>Murphy, Terrence E.</creatorcontrib><creatorcontrib>Kirchner, H. Lester</creatorcontrib><title>Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults</title><title>Urologic oncology</title><addtitle>Urol Oncol</addtitle><description>•In 1,485 older nonmuscle-invasive bladder cancer patients from 2 health systems, 23% had metabolic syndrome.•Metabolic syndrome patients were mostly males and current or former smokers.•Over median follow up of 6 years, one-third of patients had a recurrence.•We found no association between metabolic syndrome and time to nonmuscle-invasive bladder cancer recurrence. Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. We identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems’ electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index &gt;30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70–1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.</description><subject>Bladder cancer;Geriatric oncology;Outcomes;Metabolic syndrome;Multiplechronic conditions</subject><issn>1078-1439</issn><issn>1873-2496</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkE1rHDEMQE1JadK0P6HFx1xmIs94vk4lhLQNLPSSu7FlDXjx2Kk9syX_vl52k2vQQTI8SdZj7JuAWoDob_f1lqKPAesGGqhB1iDgA7sS49BWjZz6i1LDMFZCttMl-5zzHkDIUYhP7LJtJExiGq7Y_i7niE6vLgZuaP1HFPhCqzbRO-T5JdgUF-I6WJ4It5QoIPE48xDDsmX0VLlw0NkdiBuvraXEURcmcRd49Me3tptf8xf2cdY-09dzvmZPPx-e7n9Xuz-_Hu_vdhVK0ayVht4MopcIaAfTifJRamA23YQkcYZWj1pLKWfd96M0PQJA1zUIrcXJYHvNbk5jn1P8u1Fe1eIykvc6UNyyKqeX6KZRFrQ7oZhizolm9ZzcotOLEqCOltVenS2ro2UFUhXLpe_7ecVmFrJvXa9aC_DjBFC58-AoqYzuKM66InFVNrp3VvwHkcuS7Q</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Garg, Tullika</creator><creator>Young, Amanda J.</creator><creator>O'Keeffe-Rosetti, Maureen</creator><creator>McMullen, Carmit K.</creator><creator>Nielsen, Matthew E.</creator><creator>Murphy, Terrence E.</creator><creator>Kirchner, H. Lester</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202009</creationdate><title>Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults</title><author>Garg, Tullika ; Young, Amanda J. ; O'Keeffe-Rosetti, Maureen ; McMullen, Carmit K. ; Nielsen, Matthew E. ; Murphy, Terrence E. ; Kirchner, H. Lester</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-a06b7164c0cd7b51091e20fb59ce4cf03a8aa444fa6684b6c000552c03dc9bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bladder cancer;Geriatric oncology;Outcomes;Metabolic syndrome;Multiplechronic conditions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garg, Tullika</creatorcontrib><creatorcontrib>Young, Amanda J.</creatorcontrib><creatorcontrib>O'Keeffe-Rosetti, Maureen</creatorcontrib><creatorcontrib>McMullen, Carmit K.</creatorcontrib><creatorcontrib>Nielsen, Matthew E.</creatorcontrib><creatorcontrib>Murphy, Terrence E.</creatorcontrib><creatorcontrib>Kirchner, H. Lester</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Urologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garg, Tullika</au><au>Young, Amanda J.</au><au>O'Keeffe-Rosetti, Maureen</au><au>McMullen, Carmit K.</au><au>Nielsen, Matthew E.</au><au>Murphy, Terrence E.</au><au>Kirchner, H. Lester</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults</atitle><jtitle>Urologic oncology</jtitle><addtitle>Urol Oncol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>38</volume><issue>9</issue><spage>737.e17</spage><epage>737.e23</epage><pages>737.e17-737.e23</pages><issn>1078-1439</issn><eissn>1873-2496</eissn><abstract>•In 1,485 older nonmuscle-invasive bladder cancer patients from 2 health systems, 23% had metabolic syndrome.•Metabolic syndrome patients were mostly males and current or former smokers.•Over median follow up of 6 years, one-third of patients had a recurrence.•We found no association between metabolic syndrome and time to nonmuscle-invasive bladder cancer recurrence. Nonmuscle-invasive bladder cancer (NMIBC) disproportionately affects older adults who often have coexisting chronic conditions such as metabolic syndrome (MetS). Although prior research suggests that MetS is a risk factor for NMIBC, limited data exists on whether MetS is associated with NMIBC recurrence. Our objective was to evaluate the association between MetS and recurrence in older adults treated for NMIBC. We identified 1,485 older (age ≥60 years) NMIBC patients (American Joint Committee on Cancer Stage ≤1) from 2community-based health systems. Using data from the health systems’ electronic medical record, MetS was defined as the presence of three of the following: diagnosis codes indicating hypertension, hyperlipidemia, diabetes, or body mass index &gt;30. Follow up time was determined by date of the last follow up in the tumor registry and censored at 10 years. Cox proportional hazards regression of time to recurrence that accounts for the competing risk of death included adjustment for age, sex, smoking status, health system, NMIBC stage/grade, tumor size, and number of specimens with cancer. Overall, 341 patients (23%) met MetS criteria. Median follow up was 5.9 years and 582 patients (39.2%) died. Patients with MetS were more frequently male (84.2%), and mostly current/former smokers (82.6%). By 10 years, 34.1% of the cohort had experienced a recurrence. After accounting for the competing risk of death, there was no association between MetS and time to recurrence (adjusted hazard ratio, 0.88, 95% confidence interval 0.70–1.11, P = 0.28). Patients without MetS had more 0a/low grade recurrences (49.1% vs. 41.4%), though differences were not significant. We found no association between MetS and risk of NMIBC recurrence in this large, multisite cohort of older adults with NMIBC. In order to design personalized care for older NMIBC patients, future research is needed to evaluate associations between common chronic conditions and a variety of oncologic outcomes.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32409197</pmid><doi>10.1016/j.urolonc.2020.04.010</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-1439
ispartof Urologic oncology, 2020-09, Vol.38 (9), p.737.e17-737.e23
issn 1078-1439
1873-2496
language eng
recordid cdi_proquest_miscellaneous_2404045984
source Access via ScienceDirect (Elsevier)
subjects Bladder cancer
Geriatric oncology
Outcomes
Metabolic syndrome
Multiplechronic conditions
title Association between metabolic syndrome and recurrence of nonmuscle-invasive bladder cancer in older adults
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A12%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20metabolic%20syndrome%20and%20recurrence%20of%20nonmuscle-invasive%20bladder%20cancer%20in%20older%20adults&rft.jtitle=Urologic%20oncology&rft.au=Garg,%20Tullika&rft.date=2020-09&rft.volume=38&rft.issue=9&rft.spage=737.e17&rft.epage=737.e23&rft.pages=737.e17-737.e23&rft.issn=1078-1439&rft.eissn=1873-2496&rft_id=info:doi/10.1016/j.urolonc.2020.04.010&rft_dat=%3Cproquest_cross%3E2404045984%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2404045984&rft_id=info:pmid/32409197&rft_els_id=S1078143920301502&rfr_iscdi=true